Agios Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Agios Pharmaceuticals has been growing earnings at an average annual rate of 6.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 51.3% per year.
Key information
6.8%
Earnings growth rate
4.9%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | -51.3% |
Return on equity | -43.4% |
Net Margin | -1,312.6% |
Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Agios Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 27 | -352 | 120 | 0 |
30 Sep 23 | 24 | -220 | 117 | 0 |
30 Jun 23 | 20 | -210 | 121 | 0 |
31 Mar 23 | 19 | -218 | 119 | 0 |
31 Dec 22 | 14 | -232 | 122 | 0 |
30 Sep 22 | 10 | -367 | 120 | 0 |
30 Jun 22 | 6 | -369 | 118 | 0 |
31 Mar 22 | 1 | -360 | 119 | 0 |
31 Dec 21 | 0 | -357 | 121 | 0 |
30 Sep 21 | 0 | -342 | 116 | 221 |
30 Jun 21 | 0 | -337 | 117 | 221 |
31 Mar 21 | 0 | -336 | 117 | 221 |
31 Dec 20 | 0 | -329 | 115 | 0 |
30 Sep 20 | 35 | -347 | 124 | 0 |
30 Jun 20 | 61 | -374 | 129 | 0 |
31 Mar 20 | 88 | -402 | 132 | 0 |
31 Dec 19 | 0 | -301 | 102 | 214 |
30 Sep 19 | 112 | -401 | 129 | 0 |
30 Jun 19 | 102 | -389 | 127 | 0 |
31 Mar 19 | 116 | -348 | 121 | 0 |
31 Dec 18 | 94 | -346 | 114 | 0 |
30 Sep 18 | 74 | -343 | 105 | 0 |
30 Jun 18 | 70 | -325 | 91 | 0 |
31 Mar 18 | 41 | -339 | 81 | 0 |
31 Dec 17 | 43 | -315 | 71 | 0 |
30 Sep 17 | 56 | -283 | 64 | 0 |
30 Jun 17 | 53 | -269 | 58 | 0 |
31 Mar 17 | 49 | -241 | 55 | 0 |
31 Dec 16 | 70 | -198 | 51 | 0 |
30 Sep 16 | 53 | -183 | 46 | 0 |
30 Jun 16 | 50 | -160 | 44 | 0 |
31 Mar 16 | 56 | -136 | 40 | 0 |
31 Dec 15 | 59 | -118 | 36 | 0 |
30 Sep 15 | 68 | -104 | 32 | 0 |
30 Jun 15 | 96 | -60 | 28 | 0 |
31 Mar 15 | 91 | -46 | 23 | 0 |
31 Dec 14 | 65 | -54 | 19 | 0 |
30 Sep 14 | 57 | -39 | 16 | 0 |
30 Jun 14 | 30 | -55 | 14 | 0 |
31 Mar 14 | 28 | -47 | 11 | 0 |
31 Dec 13 | 26 | -44 | 10 | 0 |
30 Sep 13 | 25 | -49 | 8 | 0 |
30 Jun 13 | 25 | -40 | 7 | 0 |
Quality Earnings: 8AP is currently unprofitable.
Growing Profit Margin: 8AP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8AP is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare 8AP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8AP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 8AP has a negative Return on Equity (-43.41%), as it is currently unprofitable.